Metabolic Dependency on <i>De Novo</i> Pyrimidine Synthesis Is a Targetable Vulnerability in Platinum-Resistant Ovarian Cancer
De novo pyrimidine synthesis supports platinum resistance in ovarian cancer and can be targeted with DHODH inhibitors to suppress tumor growth, pointing to potential metabolic therapies for treating recurrent ovarian cancer.
Authors
- Guangyuan Zhao (ORCID: https://orcid.org/0000-0002-1095-8875)
- Dengrong Hao (ORCID: https://orcid.org/0000-0003-0888-7497)
- Wenan Qiang (ORCID: https://orcid.org/0000-0001-5068-7128)
- Daniela Matei (ORCID: https://orcid.org/0000-0003-2169-5035)
- Horacio Cárdenas (ORCID: https://orcid.org/0000-0002-2129-6766)
- Hao F. Zhang (ORCID: https://orcid.org/0000-0001-5089-1196)
- Yinu Wang (ORCID: https://orcid.org/0000-0003-3654-7350)
- Ana Maria Isac (ORCID: https://orcid.org/0000-0001-9795-4369)
- Vanessa Hernández (ORCID: https://orcid.org/0009-0008-0824-0814)
- U.K. Kim (ORCID: https://orcid.org/0009-0009-0046-217X)
Institutions
- Northwestern University (US)
- Jesse Brown VA Medical Center (US)
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Publication Details
- Journal
- Cancer Research
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1158/0008-5472.can-25-0043
- Citations
- 2
- Primary Topic
- Biochemical and Molecular Research
- Type
- article
- Field-Weighted Citation Impact
- 1.61